Uh-Oh Labs featured in Geekwire

Today, Uh-Oh Labs has been featured in Geekwire, highlighting the company’s recent milestones and achievements as well as exploring the backgrounds of the managing team. Kudos to Lisa Stiffler at Geekwire for the amazing writeup!

Read about Uh-Oh Labs in Geekwire here.

About Uh-Oh Labs

Uh-Oh Labs is a California-based diagnostics and health tech company with a mission to improve public health by developing affordable and accurate diagnostics. Uh-Oh Labs is developing tests through the proprietary Loop-de-LoopTM platform which enables simplicity, speed, and lower costs while providing accurate, lab-grade results. Additionally, Uh-Oh Labs is partnering with other members of the healthcare ecosystem to expand access of lab-grade diagnostics and improve the delivery of care. Uh-Oh Labs has received Emergency Use Authorization for the UOL COVID-19 Test and is developing tests for other indications including flu, STIs, and diagnostic biomarkers. Uh-Oh Labs has been funded in part by the National Institutes of Health (NIH) Rapid Acceleration of Diagnostics (RADx) initiative, as well as funding from private investors including Y Combinator.

For more information, visit us at uhohlabs.com

About Geekwire

GeekWire is a fast-growing, national technology news site with strong roots in the Seattle region and a large audience of loyal, tech-savvy readers around the globe, who follow the site for breaking news, expert analysis and unique insights into the technology industry.

Uh-Oh Labs announces FDA Authorization of the UOL COVID-19 Test for Point-of-Care

Molecular diagnostics company Uh-Oh Labs has received an emergency use authorization (EUA) from the Food and Drug Administration (FDA) for the UOL COVID-19 Test for use at the point-of-care with customers who have a CLIA Waiver, Certificate of Compliance, or Certificate of Accreditation. The UOL COVID-19 Test is a nucleic acid amplification test which allows for detection of SARS-CoV-2 RNA down to 400cp/swab within 40 minutes. In a clinical study, the UOL COVID-19 Test demonstrated a 96.1% overall agreement with an EUA authorized high-sensitivity RT-PCR assay, no false positives, and detected 97.9% of SARS-CoV-2 positive samples, excluding those with very low levels of virus.

The UOL COVID-19 Test is comprised of a reusable Instrument, disposable Test Kits, and a mobile Uh-Oh Labs Dx Pro iOS app. The UOL COVID-19 Test has been designed to simplify sample collection, running the assay, and result interpretation. The UOL COVID-19 Test has also been engineered specifically to lower per-test cost by leveraging the proprietary Loop-de-LoopTM platform. An assay can be started within 5 minutes, including sample collection and patient registration, and then runs 40 minutes “hands off”, allowing for a streamlined workflow. The results are then viewable on the Dx Pro app with plain language results, removing the need to interpret lateral flow lines.

The UOL COVID-19 Test production is already underway and available for purchase from qualified customers who have a CLIA Waiver, Certificate of Compliance, or Certificate of Accreditation. Additionally, Uh-Oh Labs is actively working towards an EUA for the UOL COVID-19 Test for non-prescription, non-laboratory use.

Uh-Oh Labs has been supported with over $15M in contracts from the National Institutes of Health as well as investments from private investors such as Y Combinator.

View the Letter of Authorization, as well as relevant documents for the UOL COVID-19 Test, on the FDA’s website.

About Uh-Oh Labs

Uh-Oh Labs is a California-based diagnostics and health tech company with a mission to improve public health by developing affordable and accurate diagnostics. Uh-Oh Labs is developing tests through the proprietary Loop-de-LoopTM platform which enables simplicity, speed, and lower costs while providing accurate, lab-grade results. Additionally, Uh-Oh Labs is partnering with other members of the healthcare ecosystem to expand access of lab-grade diagnostics and improve the delivery of care. Uh-Oh Labs has received Emergency Use Authorization for the UOL COVID-19 Test and is developing tests for other indications including flu, STIs, and diagnostic biomarkers. Uh-Oh Labs has been funded in part by the National Institutes of Health (NIH) Rapid Acceleration of Diagnostics (RADx) initiative, as well as funding from private investors including Y Combinator.

For more information, visit us at uhohlabs.com

Uh-Oh Labs receives $500K investment from Y Combinator, joins W22 batch

Uh-Oh Labs has received a $500K investment from Y Combinator and is participating in the Winter 2022 batch. Y Combinator is an American technology startup accelerator launched in March 2005, and has been used to launch more than 3,000 companies, including Stripe, Airbnb, Cruise, PagerDuty, DoorDash, Coinbase, Instacart, Dropbox, Twitch, Flightfox, and Reddit. The Y Combinator portfolio has a combined valuation of over $600B.

“Participating in Y Combinator will allow us to expand our network to some of the most successful investors and founders in the world. Our vision of democratizing accurate and low-cost diagnostics will be significantly accelerated through our participation and we believe that additional markets and partnerships can also be realized with this opportunity” Cam Ball, Uh-Oh Labs CEO said in a statement. Y Combinator is slated to run until Demo Day on March 30, 2022.

Uh-Oh Labs receives $50K grant from Johns Hopkins

Uh-Oh Labs has been awarded a $50K grant from Johns Hopkins’s Center for POC Technologies Research for STDs for its “Test, Treat, Track” proposal. The “Test, Treat, Track” proposal aims to validate the proof of concept Loop-de-Loop platform developed by Uh-Oh Labs founder and CEO, Cam Ball, in highly-sensitive detection of nucleic acids. The proposal is focused on developing accurate, low-cost diagnostics for the detection of STIs and other infectious diseases.